# WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

> **NCT01827137** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sellas Life Sciences Group** · enrollment: 20 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** Galinpepimut-S
- **BIOLOGICAL:** GM-CSF
- **OTHER:** Montanide
- **DRUG:** lenalidomide
- **DRUG:** bortezomib

## Key facts

- **NCT ID:** NCT01827137
- **Lead sponsor:** Sellas Life Sciences Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2016-12-07
- **Final completion:** 2017-11-06
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01827137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01827137, "WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01827137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*